CymaBay Therapeutics Inc CBAY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CBAY is a good fit for your portfolio.
News
-
Gilead Sciences Announces Completion of Acquisition of CymaBay
-
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, SCTL, EVRI
-
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)
-
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, IONM, WISH, FREE
-
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
-
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 111.01
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 101
- Website
- https://www.cymabay.com
Comparables
Valuation
|
Metric
|
CBAY
|
DYN
|
MORF
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 12.65 | 16.75 | 2.05 |
Price/Sales | 111.01 | — | 2,339.30 |
Price/Cash Flow | — | — | — |
Price/Earnings
CBAY
DYN
MORF
Financial Strength
|
Metric
|
CBAY
|
DYN
|
MORF
|
|---|---|---|---|
Quick Ratio | 10.70 | 2.41 | 28.43 |
Current Ratio | 10.96 | 2.53 | 28.94 |
Interest Coverage | −5.27 | — | — |
Quick Ratio
CBAY
DYN
MORF
Profitability
|
Metric
|
CBAY
|
DYN
|
MORF
|
|---|---|---|---|
Return on Assets (Normalized) | −30.06% | −88.69% | −19.79% |
Return on Equity (Normalized) | −51.97% | −114.25% | −20.47% |
Return on Invested Capital (Normalized) | −30.87% | −102.56% | −23.98% |
Return on Assets
CBAY
DYN
MORF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pnytsdfxh | Mwl | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hpgxwtm | Bvbhj | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pzxtwnwqg | Zkmtvbl | $99.6 Bil | |
MRNA
| Moderna Inc | Bhzfzzw | Qtdr | $38.8 Bil | |
ARGX
| argenx SE ADR | Tcfszkhkl | Pfhs | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Ljrxhns | Bxmx | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zshstxzl | Cppydd | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hjqqrhcf | Prbtsbj | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wsywtpsvh | Rlzbd | $12.4 Bil | |
INCY
| Incyte Corp | Rjvtfxn | Cffnp | $11.9 Bil |